Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 18, 2018 - Issue 3
Submit an article Journal homepage
162
Views
5
CrossRef citations to date
0
Altmetric
Review

A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer

Panagiotis PetrouPharmacoepidemiology-Pharmacovigilance, Pharmacy Programme, Department of Life and Health Sciences, School of Science and Engineering, University of Nicosia, Nicosia, Cyprus;Health Insurance Organisation, CyprusCorrespondence[email protected] [email protected]
View further author information
Pages 255-265 | Received 13 Dec 2017, Accepted 08 Feb 2018, Published online: 13 Mar 2018

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jianrong Yang, Jingtao Zhong, Mi Zhou, Yinghong Zhou, Peng Xiu, Feng Liu, Fuhai Wang, Zelun Li, Yuntian Tang, Yuanyuan Chen, Siyang Yao, Tao Huang, Tianqi Liu & Xiaofeng Dong. (2021) Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo. Drug Delivery 28:1, pages 844-855.
Read now

Articles from other publishers (4)

Qiuji Wu, Yi Qin, Weiting Liao, Mengxi Zhang, Yang Yang, Pengfei Zhang & Qiu Li. (2022) Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma. Therapeutic Advances in Medical Oncology 14, pages 175883592110687.
Crossref
Alireza Mosayebi, Barat Mojaradi, Ali Bonyadi Naeini & Seyed Hamid Khodadad Hosseini. (2020) Modeling and comparing data mining algorithms for prediction of recurrence of breast cancer. PLOS ONE 15:10, pages e0237658.
Crossref
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu & Ya-Chen Tina Shih. (2018) Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. PharmacoEconomics 37:3, pages 301-331.
Crossref
Bin Wu, Qiang Zhang & Jie Sun. (2018) Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. Journal for ImmunoTherapy of Cancer 6:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.